What is NanoDx?
NanoDx is at the forefront of healthcare innovation, developing cutting-edge solutions powered by its proprietary nano biosensor platform. The company's technology is designed to enhance global health outcomes, enabling individuals worldwide to lead healthier, safer, and happier lives. With a focus on diagnostics and therapeutic applications, NanoDx aims to address critical unmet needs in the healthcare sector, positioning itself as a key player in the rapidly evolving biotech and medtech industries.
How much funding has NanoDx raised?
NanoDx has raised a total of $30.5M across 7 funding rounds:
Series A
$4M
Private Equity
$1.6M
Series B
$4M
Private Equity
$2M
Private Equity
$557K
Debt
$350K
Series C
$18M
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Series B (2016): $4M supported by Provident Healthcare Capital
Private Equity (2017): $2M featuring MedScience Ventures, LLC and Provident Healthcare Capital
Private Equity (2017): $557K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Series C (2020): $18M led by Shepherd Kaplan Krochuk, LLC
Key Investors in NanoDx
MedScience Ventures, LLC
MedScience Ventures, LLC is an investment firm focused on the life sciences sector, aiming to foster innovation through strategic investments and collaborations. They engage with organizations seeking partnerships and capital within the life sciences industry.
Provident Healthcare Capital
Provident Healthcare Partners is an investment banking firm specializing in the healthcare sector, providing M&A, financing, and advisory services to privately-held companies. They are known for delivering transaction value and fostering partnerships.
Shepherd Kaplan Krochuk, LLC
Shepherd Kaplan Krochuk, LLC is an entity that has participated in NanoDx's funding rounds. Further details on their specific investment focus are not publicly available.
What's next for NanoDx?
The recent major strategic investment signals a pivotal moment for NanoDx, likely enabling the company to scale its operations, expand its product pipeline, and further penetrate the global healthcare market. This infusion of capital is expected to fuel research and development, bolster manufacturing capabilities, and support broader commercialization efforts. NanoDx is strategically positioned to leverage this financing to solidify its market leadership and drive significant advancements in diagnostic and health monitoring technologies.
See full NanoDx company page
